Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 7/20 | 0.36 |
| ▸ | CTSS | P25774 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13256192 | 0.89 | CTSL (0.43) | CTSLCTSKCTSSKMT2AALDH1A1 | |
| SCHEMBL15928425 | 0.80 | KMT2A (0.36) | CTSKKMT2AALDH1A1EPHX2MEN1 | |
| SCHEMBL23863123 | 0.79 | CTSL (0.45) | CTSLCTSKCTSSKMT2AALDH1A1 | |
| SCHEMBL15928448 | 0.79 | KMT2A (0.35) | CTSKKMT2AALDH1A1EPHX2MEN1 | |
| SCHEMBL18506639 | 0.77 | CTSS (0.47) | CTSLCTSKCTSSKMT2A | |
| SCHEMBL15928426 | 0.76 | KMT2A (0.36) | CTSKKMT2AALDH1A1EPHX2MEN1 | |
| SCHEMBL15928671 | 0.75 | EPHX2 (0.36) | CTSKCTSSKMT2AALDH1A1EPHX2 | |
| SCHEMBL17518905 | 0.75 | EPHX2 (0.36) | CTSKCTSSKMT2AALDH1A1EPHX2 | |
| SCHEMBL15928468 | 0.75 | EPHX2 (0.36) | CTSKCTSSKMT2AALDH1A1EPHX2 | |
| SCHEMBL23863121 | 0.74 | CTSL (0.42) | CTSLCTSKCTSSKMT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044156-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20160046641-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2016-02-18 | — | — | US | disclosed |
| US-20140221378-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140221380-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221380-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | IMPDH1, IMPDH2, IMPA1 | CTSL 3051/4885CTSK 4219/4885CTSS 3577/4885 |
| US-20160046641-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | IMPDH1, IMPDH2, IMPA1 | CTSL 3069/4885CTSK 4299/4885CTSS 3639/4885 |
| US-20140221378-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | IMPDH1, IMPDH2, IMPA1 | CTSL 3294/4885CTSK 4419/4885CTSS 3937/4885 |
| US-20170044156-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR | IMPDH1, IMPDH2, SAV1 | CTSL 3595/4885CTSK 4572/4885CTSS 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.